Arrowhead Pharmaceuticals Inc.

Most Recent

  • uploads///pills _
    Company & Industry Overviews

    ContraVir Stock Rose on Clinical Trial Progress Report

    ContraVir Pharmaceuticals is focused on the development of antiviral therapies with a special focus on the development of anti-HBV therapies.

    By Daniel Collins
  • uploads///AdobeStock_
    Company & Industry Overviews

    How Analysts View Arrowhead Pharmaceuticals

    In Q2, Arrowhead Pharmaceuticals reported revenues of $48.15 million—a YoY rise of 7,305.95%—ahead of the consensus estimate by $5.19 million.

    By Margaret Patrick
  • uploads///medicine _
    Company & Industry Overviews

    Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday

    On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.

    By Daniel Collins
  • uploads///Arrowhead
    Company & Industry Overviews

    Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date

    On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.

    By Daniel Collins
  • uploads///bacteria _
    Company & Industry Overviews

    Why Arbutus Biopharma Stock Plunged 24.4% Today

    Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    How Is Arrowhead Pharmaceuticals Stock Positioned?

    On October 4, Arrowhead Pharmaceuticals entered into a license and collaboration agreement with Janssen Pharmaceuticals.

    By Daniel Collins
  • uploads///nucleotide _
    Company & Industry Overviews

    Why Arrowhead Pharmaceuticals Stock Is Skyrocketing Today

    Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Analysts’ Ratings for Sorrento and Its Peers in March 2018

    Of the two analysts covering Sorrento Therapeutics in March 2018, one analyst has given it a “strong buy” recommendation.

    By Kenneth Smith
  • uploads///ARWR revenue forecast
    Company & Industry Overviews

    Taking Stock of Arrowhead Pharmaceuticals’ Financial Performance

    In 2017, Arrowhead Pharmaceuticals (ARWR) generated revenue of $31.4 million compared to $158,000 in 2016. This increase was attributable to the upfront payments Arrowhead received from Amgen.

    By Kenneth Smith
  • uploads///ARWR TRiM platform
    Company & Industry Overviews

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.

    By Kenneth Smith
  • uploads///Hepatitis B virus life cycle
    Company & Industry Overviews

    Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases

    ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.

    By Kenneth Smith
  • uploads///ARWR Drug Pipeline
    Company & Industry Overviews

    Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

    Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.

    By Kenneth Smith
  • uploads///ARWR Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Arrowhead and Its Peers

    Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.